Proteomic and Pathway Insights into Heart Failure Progression and the Modulatory Role of Empagliflozin
Abstract
Heart failure is a serious condition where the heart cannot pump blood around the body as well as it should. This can lead to tiredness, shortness of breath, and fluid buildup in the body. Heart failure affects over 64 million people worldwide and can greatly impact quality of life and life expectancy. Recent treatments have shown promise in slowing the progression of heart failure. One group of medications, called sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors), was originally developed to treat type 2 diabetes. However, they have also been shown to help patients with heart failure live longer and feel better. The SGLT2 inhibitor empagliflozin has shown to improve outcomes in heart failure patients, which is now used to treat people with or without diabetes who have heart failure. Despite these positive effects, we still do not fully understand how empagliflozin works in the body to improve heart health. In our research, we will aim to uncover how empagliflozin slows the progression of heart failure. We will do this by studying proteins—the building blocks and messengers of the body—and the biological pathways that are driving heart failure and how empagliflozin changes these proteins and pathways. Biological pathways are like networks of interacting molecules that control how cells behave. Some of these pathways may become unbalanced in heart failure, and we want to know if empagliflozin helps restore this balance. We will examine blood plasma samples to look…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.